Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods for Studying Drug Absorption: In vitro01:16

Methods for Studying Drug Absorption: In vitro

371
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
371
Methods for Studying Drug Absorption: In situ01:09

Methods for Studying Drug Absorption: In situ

385
In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
385
One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model01:15

One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model

326
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the principles of first-order kinetics. This model is vital as it provides a mathematical representation of drug behavior within the body. It also allows for the prediction and interpretation of drug absorption and elimination based on the rate of change in drug concentration over time. This model can be visualized as a plasma concentration-time profile...
326
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

789
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
789
Drug Absorption: Overview01:17

Drug Absorption: Overview

1.0K
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
1.0K
Factors Influencing Drug Absorption: Anatomical Parameters01:23

Factors Influencing Drug Absorption: Anatomical Parameters

322
Drug absorption involves the movement of drugs from the point of administration into the systemic circulation. Initially, Gastrointestinal (GI) motility propels the drug through the digestive tract and into the stomach. However, the stomach's high acidity and limited surface area restrict its role in drug absorption for most drugs. The drug then moves from the stomach to the small intestine via gastric emptying, which can be slowed by various factors, including interactions with other...
322

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing transdermal drug delivery using translational data and mechanistic based modeling.

Drug delivery and translational research·2026
Same author

Characterization of Peptide-Preservative Interaction by AlphaFold, Molecular Dynamics Simulation, and NMR Spectroscopy.

Molecular pharmaceutics·2025
Same author

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.

CPT: pharmacometrics & systems pharmacology·2025
Same author

The Impact of Permeation Enhancers on Transcellular Permeation of Small Molecule Drugs.

The journal of physical chemistry. B·2025
Same author

Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions.

Molecular pharmaceutics·2025
Same author

Plant Cell Wall Polysaccharide <i>O</i>-Acetyltransferases.

Plants (Basel, Switzerland)·2024
Same journal

Rescuing Dendritic Cells from Adjuvant Toxicity: Liposomal Ginsenoside Rh2 as a Dual-Action Strategy for Enhanced Vaccine Potency.

Molecular pharmaceutics·2026
Same journal

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma.

Molecular pharmaceutics·2026
Same journal

Dual-Targeted Radionuclide Therapy with <sup>161</sup>Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor.

Molecular pharmaceutics·2026
Same journal

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026
Same journal

Mechanistic Insight into Self-Gelation Involved in Prescription Design for Optimization of Tablet Performance.

Molecular pharmaceutics·2026
Same journal

[<sup>68</sup>Ga]Ga-DOTA-DP-UBI 29-41: A Novel <sup>68</sup>Ga-Labeled Ubiquicidin 29-41 Derivative Containing d-Proline for Bacterial Infection PET Imaging.

Molecular pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Oct 9, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

Lilly Absorption Modeling Platform: A Tool for Early Absorption Assessment.

Stephen D Stamatis1, John P Rose1

  • 1Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

Molecular Pharmaceutics
|December 16, 2021
PubMed
Summary
This summary is machine-generated.

A new noncompartmental oral drug absorption modeling framework, the Lilly Absorption Modeling Platform (LAMP), was developed. This platform accurately predicts drug absorption by simulating gastrointestinal physiology and critical absorption processes.

Keywords:
PBBM modelsabsorption modelingcompartmental modelsmaximum absorbable doseoral absorptionplug flow

More Related Videos

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.0K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.8K

Related Experiment Videos

Last Updated: Oct 9, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.0K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.8K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Computational Modeling and Simulation

Background:

  • Oral drug absorption modeling has evolved significantly over 40 years.
  • Compartmental modeling has dominated absorption modeling for the past two decades.

Purpose of the Study:

  • Introduce a novel noncompartmental absorption modeling framework, the Lilly Absorption Modeling Platform (LAMP).
  • To balance speed, consistency, and ease of use with minimal complexity for accurate gastrointestinal (GI) physiology and oral absorption process modeling.

Main Methods:

  • Developed the Lilly Absorption Modeling Platform (LAMP) connecting a well-mixed stomach to a plug-flow small intestine model.
  • Incorporated intestinal mixing and a tunable precipitation model (rapid nucleation, slow growth) within the continuous tube framework.
  • Validated the LAMP model using predictions of fraction absorbed and maximum absorbable dose for clinical compounds.

Main Results:

  • The LAMP framework successfully models essential GI physiology and oral absorption.
  • Model validation demonstrated accurate predictions for fraction absorbed and maximum absorbable dose.
  • The noncompartmental approach offers a viable alternative to traditional compartmental models.

Conclusions:

  • The Lilly Absorption Modeling Platform (LAMP) provides a robust, efficient, and user-friendly noncompartmental framework for oral drug absorption modeling.
  • LAMP accurately captures key aspects of GI physiology and drug absorption processes.
  • This platform can aid in predicting drug behavior and optimizing development for clinical compounds.